Ethics

2024

Operation and Effectiveness Evaluation of the ISO 37001 Anti-Bribery Management System
- Conducted the 2024 recertification audit for ISO 37001 and successfully maintained the certification
- All employees signed company-wide pledges to comply with anti-bribery and fair trade practices

Completed the preparation, retention, and submission of 2023 economic benefit expenditure reports to the Health Insurance Review and Assessment Service (HIRA)

Promoted and provided training on the disclosure system for expenditure reports

Continuously enhanced the economic benefit reporting system

Delivered CP (Compliance Program) training using multiple channels, including offline sessions, online modules, and real-time virtual training

Conducted information security campaigns and inspections of office environments

Published CP Letters on a quarterly basis and actively promoted key compliance messages

Completed competency-building education for compliance officers and CP practitioners (CCP certification)

Implemented gift and entertainment campaigns, including the message: "Do not give or receive holiday gifts"

Conducted continuous monitoring of product explanation meetings

Supported CP operations of affiliated group companies

Underwent regular CP audits conducted by partner companies(LG Chem, AstraZeneca Korea, and Lundbeck Korea)

2023

1st ex-post audit on ISO 27001 (information security)/ISO 27701 (personal information protection) international standard certifications

1st ex-post audit on ISO 37001 (anti-bribery management system) international standard certification (after certification renewal)

2022

Officers and employees company-wide sign the anti-corruption and fair competition pledge (1,907 officers and employees)

General and intensive fair-competition training for new transferees of the sales and marketing department for the first half of the year (26 employees)

CP/anti-competition training for interns (16 interns)

Became the first company to simultaneously obtain ISO27001(information security) and ISO27701(personal information protection) certifications

Signed the 2022 Korean Association for Industrial Technology Security Project for Enhancement of Security at Mid-Size Enterprises and received government subsidies

Conducted due diligence on product information sessions and symposia where lodging is provided

5th advanced development phase for the economic benefit and expenditures reporting system (process automation and improved monitoring efficiency)

General and intensive fair-competition training for new transferees of the sales and marketing department for the second half of the year

Received a regular CP audit for LG Life Sciences partners

Received a regular CP audit for AstraZeneca Korea partners

Regular update of the 2022 company-wide corruption risk assessment report

Conducted 2022 internal audit on anti-corruption management (random selection of 36 teams from headquarters, research center, and factories)

2022 Anti-corruption CEO management review report

Anti-corruption training for all employees (1,847 persons)

2022

Officers and employees company-wide sign the anti-corruption and fair competition pledge (1,907 officers and employees)

General and intensive fair-competition training for new transferees of the sales and marketing department for the first half of the year (26 employees)

CP/anti-competition training for interns (16 interns)

Became the first company to simultaneously obtain ISO27001(information security) and ISO27701(personal information protection) certifications

Signed the 2022 Korean Association for Industrial Technology Security Project for Enhancement of Security at Mid-Size Enterprises and received government subsidies

Conducted due diligence on product information sessions and symposia where lodging is provided

5th advanced development phase for the economic benefit and expenditures reporting system (process automation and improved monitoring efficiency)

General and intensive fair-competition training for new transferees of the sales and marketing department for the second half of the year

Received a regular CP audit for LG Life Sciences partners

Received a regular CP audit for AstraZeneca Korea partners

Regular update of the 2022 company-wide corruption risk assessment report

Conducted 2022 internal audit on anti-corruption management (random selection of 36 teams from headquarters, research center, and factories)

2022 Anti-corruption CEO management review report

Anti-corruption training for all employees (1,847 persons)

2021

24th amendment to CP SOP

Conducted anti-corruption and CP training for all employees for 2021

Conducted training and instruction of marketing department personnel on rebate prevention and fair competition (completed by 413 employees)

Provided general and intensive instructions on fair competition for newly transferred members of the sales and marketing department (completed by 20 employees)

ISO37001 certification renewed

Continuing education and renewal of certification for certified compliance professionals (CCPs) (current number of certified professionals: 7 Class I professionals, 1 Class II professional)

ISO37001 examiner certification acquired (2 employees)

Expanded communication channels on compliance regulations and laws (FAQ notice and internal inquiry boards)

11th CP committee (a total of 62 new sales and marketing plans reviewed, 9 sent back)

Exhaustive review of sales and marketing budget expenditures

Three instances of on-site due diligence on product information sessions where invitees were provided lodging

2020

Made the 23rd revision for CP SOP

Strengthened CP monitoring for co-promotion product marketing activities

Advanced the economic interest expense report system (3rd time)

Tightened standards for product presentations targeting health professionals

Created online CP Q&A/FAQ bulletin boards

2020: Attended KPBMA ethical management academy/workshop

2020: Company-wide anti-corruption training

2020: Sales/marketing CP training

ISO 37001 ex-post audit (3rd year)

Added 1 CCP-certified person

2019

Conducted follow-up review for ISO 37001 (2nd year)

Advanced the economic interest expense report system (2nd time)

Invited an outside expert to provide compliance training to employees

Published CP Handbook 5th Edition (Supplementary)

Ensured that all CP staff had CCP Level 1 qualification

Reinforced the CP operating process

2018

Obtained ISO 37001 certification of anti-bribery management
※ International anti-bribery management system

Developed an economic interest expense report system

Published CP Handbook 5th Edition

Ensured that 3 employees newly acquired Certified Compliance Professional (CCP) Level 1

2017

Received AA rating in CP rating 2 consecutive times
(first in the pharmaceutical industry)

Send CP letters to all management and employees twice a month
(send relevant laws/regulations and issues)

Constructed ‘economic profit expenditure report’ system

2016

Pre-post inspection for constructing a CP monitoring CES system

Publish CP FAQ guidebook

Newly establish the Daewoong Pharmaceutical ‘webzine’ compliance board

CP work organization → Legal team/CP team operated separately

2015

Received AA rating in CP ratings
(first in the pharmaceutical industry, highest rating)

Awarded ‘Presidential Medal’ on Fair Trade Day for autonomous compliance manager

Published 4th CP handbook

Foster holders of grade 1 compliance management experts

Operate legal CP team (appointed legal advisor attorney)

2014

Published third CP handbook

Newly organized CP team directly under the CEO

In-company cyber classroom

Newly established fair trade training course
(8 classes, supported by the company)

Published ethical management handbook

2011

Published second CP handbook

Enacted integrated CP regulations for Daewoong Group

2008

Published the first CP handbook in the pharmaceutical industry

2007

Introduced fair trade autonomous compliance program

Established compliance organization